MEDINET Co., Ltd. announced that it expects to receive ¥22.44 million in funding from Macquarie Bank Limited, Investment Arm
August 15, 2021
Share
MEDINET Co., Ltd. announced a private placement of 340,000 18th stock acquisition rights at ¥66 per stock acquisition right for gross proceeds of ¥22,440,000 on August 16, 2021. The transaction included participation from returning investor Macquarie Bank Limited, Investment Arm. The potential shares from the issuance of stock acquisition rights will be 34,000,000 shares. The initial exercise price of stock acquisition rights ¥78.85 for a period from September 2, 2021 to September 1, 2023. The transaction will happen through third party allocation. The company will incur issuance expenses with respect to the transaction including registration and license taxes, attorney's fees, fair value calculation costs for the stock acquisition rights, securities registration statement preparation costs, etc. The issue date for stock acquisition rights will be September 1, 2021. The transaction has been approved at board of directors’ meeting of the company.
MEDINET Co., Ltd. is a Japan-based company mainly engaged in cell processing industry and cellular medical products business. It operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. It also provides comprehensive support services for immune cell therapy.